Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference
06:30am, Thursday, 08'th Jul 2021
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
Here's What Drove Gene Editing Stocks Higher This Week
12:48pm, Friday, 02'nd Jul 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
02:04pm, Wednesday, 30'th Jun 2021
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Why Beam Therapeutics Jumped Today
12:22pm, Monday, 28'th Jun 2021
A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution.
Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
06:30am, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John
Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners
12:16pm, Tuesday, 11'th May 2021
Beam Therapeutics Inc (NASDAQ: BEAM) reported a wider Q1 net loss of $201.6 million compared to $31.7 million a year ago, on higher R&D costs of $190.1 million, up from $21.5 million in Q1 2020. I
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Lags Revenue Estimates
08:16am, Tuesday, 11'th May 2021
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -365.28% and -99.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the sto
Buying This Beaten-Down ETF Could Make You a Fortune Over the Next 10 Years
05:52am, Friday, 07'th May 2021
It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.
Will Beam Therapeutics Inc. (BEAM) Report Negative Q1 Earnings? What You Should Know
03:47pm, Tuesday, 04'th May 2021
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting
04:41pm, Tuesday, 27'th Apr 2021
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that th
Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing
10:12am, Tuesday, 20'th Apr 2021
Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company's Pioneering Work in Developing Base Editors
3 Hot Healthcare Stocks Cathie Wood Is Buying in April
06:01am, Saturday, 17'th Apr 2021
Here's why she likes them so much.
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
06:30am, Monday, 15'th Mar 2021
Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021
Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
06:15am, Monday, 15'th Mar 2021
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that dr
